Cover Image
市場調查報告書

印度醫療藥品市場:主要國內企業 (2015年)

The Indian Pharmaceutical Market - Leading Domestic Companies 2015

出版商 GMR Data Ltd 商品編碼 339655
出版日期 內容資訊 英文 152 Pages
訂單完成後即時交付
價格
Back to Top
印度醫療藥品市場:主要國內企業 (2015年) The Indian Pharmaceutical Market - Leading Domestic Companies 2015
出版日期: 2015年09月14日 內容資訊: 英文 152 Pages
簡介

印度醫療藥品市場大幅成長是因為美國學名藥市場。大型企業年間收益50%來自美國學名藥市場。但由於美國FDA的檢查更加嚴格,前十大公司皆收過來自FDA的警告。

本報告針對印度醫療藥品市場調查、提供主要國內市場的市場全體動向、市場佔有率、前十大公司檔案、財務分析、SWOT分析。

第1章 摘要整理

  • 摘要整理
  • 調查分析方法
  • 市場促進因素與阻礙因素
    • 促進因素
      • 美國學名藥市場
      • 合作、收購、合併
      • 專利到期
      • 國內醫療費提高
      • 半規範與新興醫療藥品市場地區擴大
      • 藥劑生產、製造經濟
      • 政府支援
    • 阻礙因素
      • 業界效率低與無法配合的法規
      • 藥價上限
      • 知識產權/強制許可
      • 不適當的醫療保險

第2章 印度醫療藥品市場概要

  • 印度醫療藥品部門發展
    • 主要改革/法規制度
    • 顧客/使用者
    • 藥價/補償
    • 競爭環境

第3章 印度醫療藥品市場收益

  • 國內
  • 出口
  • 市場佔有率

第4章 前十大公司:2015年

  • Sun Pharmaceutical Industries Ltd
  • Dr Reddy's Laboratories Ltd.
  • Lupin Ltd
  • Cipla Ltd
  • Zydus Cadila Healthcare Ltd
  • Aurobindo Pharma Limited
  • Glenmark Pharmaceuticals Ltd.
  • Jubilant Life Sciences
  • Torrent Pharmaceuticals Limited
  • Wockhardt Limited
    • 企業檔案
    • 財政分析
    • SWOT分析

第5章 專家見解

  • Cipla Ltd
  • Cadila Healthcare
  • IPCA Laboratories

圖表

目錄
Product Code: IN10PHARM

GMR Data's new pharmaceutical market report 'The Indian Pharmaceutical Market - Leading Domestic Companies 2015 ' is released today

This report discusses the Indian pharmaceutical industry in depth, with specific focus on the ten leading domestic India pharmaceutical companies; their key financials since FY2011; their key global markets; their Merger, Acquisition and Joint Venture activity; their Research & Development spending; as well as Strength, Weakness, Opportunity and Threats that each individual company faces. This report also offers a snapshot of the key financials in the India pharmaceutical sector; import / export values, and where the India based pharmaceutical companies are generating their revenue globally. The report concludes with interviews with directors of Ipca Laboratories, Cadila Healthcare and Cipla.

The Indian Pharmaceutical Market - Leading Domestic Companies 2015 also highlights what drives, or restrains, the market for these leading companies;

Key Drivers

  • US Generics Market
  • JV, Acquisitions & Mergers
  • Patent Cliff
  • Increased Domestic Health Spending
  • Geographic Expansion into Semi-Regulated and Emerging Pharma Markets
  • Economies in Drug Production/Manufacture
  • Governmental Support

Key Restraints

  • Industry Inefficiencies
  • Regulatory Non-Compliance
  • Price Ceilings
  • Intellectual Property Rights / Compulsory Licence
  • Inadequate Health Insurance, India

The US generics market has been a massive growth driver for the India pharmaceutical market, with many leading companies in GMR Data's list generating over 50% of their annual revenues from the US generics market. However with access to the US market comes increased scrutiny from the US FDA; nearly all the companies in the top ten have faced warnings from the FDA; ranging from minor procedural infractions to complete manufacturing shutdown.

The report contains over 130 tables & figures across 152 pages and concludes with 3 exclusive interviews with managing directors of 3 leading Indian pharmaceutical companies;

  • Cipla
  • Cadila Healthcare
  • IPCA Laboratories

Table of Contents

1 Executive Summary

  • 1.1 Executive Summary
  • 1.2 Research and Analysis Methods
  • 1.3 Drivers & Restraints
    • 1.3.1 Drivers
      • 1.3.1.1 US Generics Market
      • 1.3.1.2 JV, Acquisitions & Mergers
      • 1.3.1.3 Patent Cliff
      • 1.3.1.4 Increased Domestic Health Spending
      • 1.3.1.5 Geographic Expansion into Semi-Regulated and Emerging Pharma Markets
      • 1.3.1.6 Economies in Drug Production/Manufacture
      • 1.3.1.7 Governmental Support
    • 1.3.2 Restraints
      • 1.3.2.1 Industry Inefficiencies and Regulatory Non-Compliance
      • 1.3.2.2 Price Ceilings
      • 1.3.2.3 Intellectual Property Rights / Compulsory Licence
      • 1.3.2.4 Inadequate Health Insurance, India

2 Indian Pharmaceutical Market Overview

  • 2.1 Evolution of the India Pharmaceutical Sector
    • 2.1.1 Key Reforms/Regulations
    • 2.1.2 Customers/End-Users
    • 2.1.3 Pricing/Reimbursement
    • 2.1.4 Competitive Landscape

3 India Pharmaceutical Market Revenue

  • 3.1 Pharmaceutical Market Revenue - Domestic
  • 3.2 Pharmaceutical Market Revenue - Export
  • 3.3 Domestic Pharmaceutical Drugs Market Share

4 - The 10 Leading Indian Pharmaceutical Companies 2015

  • 4.0.1 The Top Ten India Pharmaceutical Companies FY2015, by Revenue
  • 4.0.2 The Top Ten Domestic & Foreign Revenue Generators FY2015
  • 4.0.3 The Top Ten R&D Spending FY2015
  • 4.1 Sun Pharmaceutical Industries Ltd
    • 4.1.1 Sun Pharma Company Profile
    • 4.1.2 Sun Pharma Financial Analysis
    • 4.1.3 Sun Pharma SWOT Analysis
      • 4.1.3.1 Strengths
        • 4.1.3.1.1 Robust R&D Spending
        • 4.1.3.1.2 Strong Drugs Pipeline
        • 4.1.3.1.3 Strong Position in Key Markets
      • 4.1.3.2 Weaknesses
        • 4.1.3.2.1 Export Dependency
      • 4.1.3.3 Opportunities
        • 4.1.3.3.1 Capitalisation on the Ranbaxy Acquisition
        • 4.1.3.3.2 Further Acquisition
    • 4.1.3.4 Threats
      • 4.1.3.4.1 FDA warnings
      • 4.1.3.4.2 Ranbaxy Merger Issues
  • 4.2 Dr Reddy's Laboratories Ltd.
    • 4.2.1 Dr Reddy's Company Profile
    • 4.2.2 Dr Reddy's Financial Analysis
    • 4.2.3 Dr Reddy SWOT Analysis
      • 4.2.3.1 Strengths
        • 4.2.3.1.1 Global Presence through Strategic Acquisitions and Partnerships
        • 4.2.3.1.2 Generic Sales in Key Geographies
        • 4.2.3.1.3 Strong Operational Infrastructure and Robust Base for Research
      • 4.2.3.2 Weaknesses
        • 4.2.3.2.1 Increased R&D spending to put Pressures on Margins
      • 4.2.3.3 Opportunities
        • 4.2.3.3.1 Growth in US Generic Market
        • 4.2.3.3.2 Biosimilars Market Opportunity
      • 4.2.3.4 Threats
        • 4.2.3.4.1 Economic / Political Uncertainties in Some Markets
        • 4.2.3.4.2 Manufacturing Issues Leading to FDA Scrutiny / Drug Recalls
  • 4.3 Lupin Ltd
    • 4.3.1 Lupin Company Profile
    • 4.3.2 Lupin Financial Analysis
    • 4.3.3 Lupin SWOT Analysis
      • 4.3.3.1 Strengths
        • 4.3.3.1.1 Strong US Presence
        • 4.3.3.1.2 Diverse ROW Sales Revenue
        • 4.3.3.1.3 Acquisitions / JVs
      • 4.3.3.2 Weaknesses
        • 4.3.3.2.1 Net Exporter
      • 4.3.3.3 Opportunities
        • 4.3.3.3.1 Japan
        • 4.3.3.3.2 Anti-TB Market
      • 4.3.3.4 Threats
        • 4.3.3.4.1 Consolidation in the US Pharmaceutical Industry
  • 4.4 Cipla Ltd
    • 4.4.1 Cipla Company Profile
    • 4.4.2 Cipla Financial Analysis
      • 4.4.3.1 Strengths
        • 4.4.3.1.1 Global Presence
        • 4.4.3.1.2 Numerous Global JVs/Acquisitions
        • 4.4.3.1.3 R&D Focus
      • 4.4.3.2 Weaknesses
        • 4.4.3.2.1 Robust Competition
      • 4.4.3.3 Opportunities
        • 4.4.3.3.1 Focus on Key Markets
        • 4.4.3.3.2 Successful Launch of Late Stage Pipeline
        • 4.4.3.3.3 Investment in MMV
      • 4.4.3.4 Threats
        • 4.4.3.4.1 FDA Approval
        • 4.4.3.4.2 Domestic Pricing Regulations
  • 4.5 Zydus Cadila Healthcare Ltd
    • 4.5.1 Cadila Company Profile
    • 4.5.2 Cadila Financial Analysis
    • 4.5.3 Cadila SWOT Analysis
      • 4.5.3.1 Strengths
        • 4.5.3.1.1 Drug Approval History
        • 4.5.3.1.2 Solid Platforms in Key Markets
        • 4.5.3.1.3 JVs, Alliances & Subsidiaries
      • 4.5.3.2 Weaknesses
        • 4.5.3.2.1 Delays in Approval
        • 4.5.3.2.2 Price Controls
      • 4.5.3.3 Opportunities
        • 4.5.3.3.1 R&D Strength
        • 4.5.3.3.2 Opportunities to Strengthen their Global Markets
      • 4.5.3.4 Threats
        • 4.5.3.4.1 Further FDA Warnings
  • 4.6 Aurobindo Pharma Limited
    • 4.6.1 Aurobindo Company Profile
    • 4.6.2 Aurobindo Financial Analysis
    • 4.6.3 Aurobindo SWOT Analysis
      • 4.6.3.1 Strengths
        • 4.6.3.1.1 Acquisitions / JVs
        • 4.6.3.1.2 Sales from both Domestic & Global Market
        • 4.6.3.1.3 Strong in-house R&D Base
      • 4.6.3.2 Weaknesses
        • 4.6.3.2.1 Unscheduled Changes in Management
      • 4.6.3.3 Opportunity
        • 4.6.3.3.1 Strength of Approved Fillings, Internationally
        • 4.6.3.3.2 Strong Pipeline
        • 4.6.3.3.3 Geographical Growth
      • 4.6.3.4 Threats
        • 4.6.3.4.1 Competition
        • 4.6.3.4.2 Regulatory & Compliance Risks
        • 4.6.3.4.3 Pricing risks
  • 4.7 Glenmark Pharmaceuticals Ltd.
    • 4.7.1 Glenmark Company Profile
    • 4.7.2 Glenmark Financial Analysis
    • 4.7.3 Glenmark SWOT Analysis
      • 4.7.3.1 Strengths
        • 4.7.3.1.1 Strong R&D Base
        • 4.7.3.1.2 Revenue from Multiple Markets
      • 4.7.3.2 Weakness
        • 4.7.3.2.1 Organic Growth
      • 4.7.3.3 Opportunities
        • 4.7.3.3.1 Continued Growth in Global Markets
      • 4.7.3.4 Threats
        • 4.7.3.4.1 Litigation
  • 4.8 Jubilant Life Sciences
    • 4.8.1 Jubilant Company Profile
    • 4.8.2 Jubilant Financial Analysis
      • 4.8.3.1 Strengths
        • 4.8.3.1.1 Attracts Foreign Investment
        • 4.8.3.1.2 Multiple Global Production Bases
      • 4.8.3.2 Weaknesses
        • 4.8.3.2.1 R&D Effectiveness
      • 4.8.3.3 Opportunities
        • 4.8.3.3.1 Expanding Global Drugs Pipeline
        • 4.8.3.3.2 Geographical Expansion
        • 4.8.3.3.3 Significant Subsidiaries / Collaborations
      • 4.8.3.4 Threats
        • 4.8.3.4.1 Rising Raw Material Prices
  • 4.9 Torrent Pharmaceuticals Limited
    • 4.9.1 Torrent Company Profile
    • 4.9.2 Torrent Financial Analysis
    • 4.9.3 Torrent SWOT Analysis
      • 4.9.3.1 Strengths
        • 4.9.3.1.1 Revenue Generated in Diverse Geographical Markets
        • 4.9.3.1.2 Integration of Elder Pharma
      • 4.9.3.2 Weaknesses
        • 4.9.3.2.1 R&D Spending
      • 4.9.3.3 Opportunities
        • 4.9.3.3.1 Growth in Torrent's Global Markets
        • 4.9.3.3.2 Global Drugs Pipeline
      • 4.9.3.4 Threats
        • 4.9.3.4.1 Drug Price Controls
        • 4.9.3.4.2 Litigation
  • 4.10 Wockhardt Limited
    • 4.10.1 Wockhardt Company Profile
    • 4.10.2 Wockhardt Financial Analysis
    • 4.10.3 Wockhardt SWOT Analysis
      • 4.10.3.1 Strengths
        • 4.10.3.1.1 R&D Spending
        • 4.10.3.1.2 Multiple Markets Generating Revenue
      • 4.10.3.2 Weaknesses
        • 4.10.3.2.1 Regulatory Warnings
        • 4.10.3.2.2 US Sales Growth
      • 4.10.3.3 Opportunity
        • 4.10.3.3.1 Further M&A
      • 4.10.3.4 Threat
        • 4.10.3.4.1 Increased Regulatory Scrutiny

5 Expert Opinion

  • 5.1 Cipla Ltd
  • 5.2 Cadila Healthcare
  • 5.3 IPCA Laboratories

List of Tables

  • Table 1.1 Total Revenue for Ten Leading Indian Pharmaceutical Companies FY2015 ($/m)
  • Table 1.3.1 Drivers and Restraints of the Leading Domestic Companies in the India Pharmaceutical Market
  • Table 1.3.2 Indian Pharmaceutical Companies M&A /JV Activity
  • Table 1.3.3 High Earning Drugs Scheduled to Exit US Patent to 2016 ($/bn)
  • Table 1.3.4 India GDP & Healthcare Spending, 2013 ($/bn)
  • Table 1.3.5 Forecast of Public Vs Private Healthcare Spending, India 2005 -2020 ($/bn, %)
  • Table 1.3.6 Key Adult Health Risk Factors, India, 2013
  • Table 1.3.7 Diabetes Population, Prevalence and Healthcare Expenditure, India, 2013 ($)
  • Table 1.3.8 Forecast of Population & GDP Growth, India 1990-2020 ($ & %)
  • Table 1.3.9 Examples of Indian & Foreign Pharmaceutical Companies Partnerships 2009 - 2014
  • Table 1.3.10 Japanese Companies Investments in India Pharmaceutical Companies 2008-2012 ($)
  • Table 2.1 Multinational Vs Domestic Companies Pharmaceutical Market Dominance 1952-2000
  • Table 2.2 Rural Vs Urban Hospital & Doctor Ratios, India, 2014
  • Table 2.3 Healthcare Expenditure - Reimbursement Source India, 2014
  • Table 2.4 Comparative Analysis - Healthcare Expenditure, India Vs Global, 2014 ($)
  • Table 3.1 Pharmaceutical Market Revenue India 2005-2015 ($/bn)
  • Table 3.2 Export Revenue by Geographical Region 2011-2015 ($/m)
  • Table 3.3 Pharmaceutical Market Revenue India 2005-2015 ($/bn)
  • Table 3.4 Indian Pharmaceutical Market - Products Market Share, 2015 (%)
  • Table 4.0.1 Top 10 Indian Pharmaceutical Companies, by Revenue, FY2015 ($/m)
  • Table 4.0.2 Top 10 Indian pharmaceutical Companies by Domestic & Foreign Revenue FY2015 ($/m)
  • Table 4.0.3 Top 10 Indian Pharmaceutical Companies R&D Spending, FY2015 ($/m)
  • Table 4.1.1 Sun Pharma Financial Highlights 2011-2015 ($/m)
  • Table 4.1.2 Sun Pharma Geographical Revenue Mix FY2015
  • Table 4.1.3 Sun Pharma SWOT Analysis
  • Table 4.1.4 Sun Pharma's R&D Spending 2011-2015 ($/m & %)
  • Table 4.1.5 Sun Pharma Pharma's ANDA Approvals, in the US, to March 2015
  • Table 4.1.6 Sun Pharma's US & India Revenue FY2011-2015 ($/m & %)
  • Table 4.1.7 Key Sun / Ranbaxy Partnerships 2011-2015
  • Table 4.1.8 Key Sun / Ranbaxy M&A /JV Activity
  • Table 4.2.1 Dr Reddy's Financial Highlights 2011-2015 ($/ %)
  • Table 4.2.2 Dr Reddy's Geographical Revenue Mix FY2015 ($)
  • Table 4.2.3 Dr Reddy SWOT Analysis
  • Table 4.2.4 Dr Reddy's Key Acquisitions / Partnerships 2005-2015
  • Table 4.2.5 Dr Reddy's Geographical Generic Sales Revenue FY2015
  • Table 4.2.6 Dr Reddy's Gross Revenue Vs R&D Spending 2011-2015 ($/ %)
  • Table 4.3.1 Lupin Financial Highlights 2011-2015 ($/m)
  • Table 4.3.2 Lupin's US Generic Sales Revenue 2011-2015 ($/m)
  • Table 4.3.3 Lupin Revenue Geographical Mix FY2015 ($/m)
  • Table 4.3.4 Lupin R&D Spending 2011-2015 ($/m & %)
  • Table 4.3.5 Lupin SWOT Analysis
  • Table 4.3.6 Lupin ROW Revenue Breakdown FY2015 ($/m)
  • Table 4.3.7 Lupin Key Acquisitions / JVs 2011-2015
  • Table 4.3.8 Lupin's US Generics Revenues 2011-2015 ($/m)
  • Table 4.3.9 Lupin's Japan Revenues 2011-2015 ($/m)
  • Table 4.4.1 Cipla Financial Highlights 2011-2015 ($/m)
  • Table 4.4.2 Cipla Geographical Revenue Mix FY2014 ($/m)
  • Table 4.4.3 Cipla SWOT Analysis
  • Table 4.4.4 Cipla's Global JVs/Acquisitions 2013-2015
  • Table 4.4.5 R&D Spending 2011-2015 ($/m & %)
  • Table 4.5.1 Cadila Financial Highlights 2011-2015 ($/m)
  • Table 4.5.2 Cadila Revenue Geographical Mix FY2015 ($/m)
  • Table 4.5.3 Cadila SWOT Analysis
  • Table 4.5.4 Cadila Revenue US, India & Others FY2015 ($/m)
  • Table 4.5.5 Cadila Therapeutic Area of Branded Formulation Sales, India, FY2015 ($/m & %)
  • Table 4.5.6 Key JV /Alliances Zydus Cadila 2010-2015
  • Table 4.5.7 Cadila's R&D Spending 2011-2015 ($/m & %)
  • Table 4.6.1 Aurobindo Financial Highlights 2011-2015 ($/m)
  • Table 4.6.2 Aurobindo Revenue Breakdown by Geographical Area 2015 ($/m & %)
  • Table 4.6.3 Aurobindo Revenue Breakdown, by Product Area, 2015 ($/m & %)
  • Table 4.6.4 Aurobindo SWOT Analysis
  • Table 4.6.5 Key Contracts for Aurobindo 2009-2014 ($/m)
  • Table 4.6.6 Aurobindo Revenue breakdown by Geographical Area, 2015, ($/m & %)
  • Table 4.6.7 Aurobindo Revenue breakdown by Geographical Area 2015 ($/m & %)
  • Table 4.6.8 Aurobindo R&D Spending 2011-2015 ($/m & %)
  • Table 4.6.9 Aurobindo Drug Filings Fy2015 & Cumulative Historical Total
  • Table 4.6.10 Aurobindo FY2015 US FDA Drug Approvals
  • Table 4.7.1 Glenmark Financial Highlights 2011-2015 ($/m)
  • Table 4.7.2 Glenmark SWOT Analysis
  • Table 4.7.3 Glenmark R&D Spending 2011-2015 ($/m & %)
  • Table 4.7.4 Glenmark Geographical Revenue Mix FY2014 ($/m)
  • Table 4.7.5 Glenmark Global Revenue Breakdown FY2014 & FY2015 ($/m & %)
  • Table 4.8.1 Jubilant Financial Highlights 2011-2015 ($/m)
  • Table 4.8.2 Jubilant Geographical Revenue Mix FY2015 ($/m & %)
  • Table 4.8.3 Jubilant SWOT Analysis
  • Table 4.8.4 Jubilant R&D Spending 2011-2015 ($/m & %)
  • Table 4.8.5 Jubilant Subsidiary Activity
  • Table 4.8.6 Jubilant Key Recent Collaboration Activity
  • Table 4.9.1 Torrent Financial Highlights 2011-2015 ($/m)
  • Table 4.9.2 Torrent Revenue Breakdown by Geographical Area FY2015 ($/m & %)
  • Table 4.9.3 Torrent SWOT Analysis
  • Table 4.9.4 Torrent Geographical Revenue Mix FY2015 ($/m & %)
  • Table 4.9.5 Torrent R&D Spending 2011-2015 ($/m & %)
  • Table 4.9.6 Torrent's Global Revenue FY2014-FY2015 ($/m & %)
  • Table 4.10.1 Wockhardt Financial Highlights 2011-2015 ($/m)
  • Table 4.10.2 Wockhardt SWOT Analysis
  • Table 4.10.3 Wockhardt R&D Spending 2011-2015 ($/m & %)
  • Table 4.10.4 Wockhardt Geographical Revenue Mix FY2015
  • Table 4.10.5 Wockhardt's US Revenue Vs Total Global Revenue FY2011-FY2015 ($/m & %)

List of Figures

  • Figure 1.1 Forecast of Public Vs Private Healthcare Spending, India 2005 -2020 ($/bn)
  • Figure 2.1 Evolution of the India Pharmaceutical Sector 1970-2010
  • Figure 2.2 Rural v/s Urban Split of Indian Population
  • Figure 3.1 Pharmaceutical Market Revenue India 2004-2014
  • Figure 3.2 Export Revenue, by Region, 2011 (%)
  • Figure 3.3 Export Revenue, by Region, 2015 (%)
  • Figure 3.4 Export Revenue, by Region, 2011-2015 ($/bn P/A)
  • Figure 3.5 Indian Pharmaceutical Market - Products Market Share 2015 (%)
  • Figure 4.0.1 Top 10 Indian Pharmaceutical Companies, Domestic & Foreign Revenue FY2015 ($/m)
  • Figure 4.0.2 Top 10 Indian Pharmaceutical Companies R&D Spending, FY2015 ($/m)
  • Figure 4.1.1 Financial Highlights 2011-2015 ($/m)
  • Figure 4.1.2 Revenue Geographical Mix FY2015
  • Figure 4.2.1 Dr Reddy's Financial Highlights 2011-2015 ($/m)
  • Figure 4.2.2 Dr Reddy's Geographical Revenue Mix FY2015
  • Figure 4.2.3 Dr Reddy's Generic Sales Revenue, by Geography FY2015
  • Figure 4.2.4 India's Total Volume Share of US Generics Market 2006-2013 (%)
  • Figure 4.3.1 Lupin Financial Highlights 2011-2015 ($/m)
  • Figure 4.3.2 Lupin Revenue, by Geography, FY2015
  • Figure 4.3.3 Lupin ROW Revenue Breakdown FY2015
  • Figure 4.4.1 Cipla's Financial Highlights 2011-2015 ($/m)
  • Figure 4.4.2 Cipla Revenue, by Geography, FY2014
  • Figure 4.5.1 Cadila Financial Highlights 2011-2015 ($/m)
  • Figure 4.5.2 Cadila Formulations Revenue, by Geography FY2015
  • Figure 4.6.1 Aurobindo Financial Highlights 2011-2015 ($/m)
  • Figure 4.6.2 Aurobindo Revenue, by Geographical Area, FY2015 (%)
  • Figure 4.6.3 Aurobindo Revenue Breakdown, by Product Area, FY2015 (%)
  • Figure 4.6.4 Aurobindo Revenue, by Geographical Area, FY2015 (%)
  • Figure 4.7.1 Glenmark Financial Highlights 2011-2015 ($/m)
  • Figure 4.7.2 Glenmark Revenue, by Geography, FY2014 (%)
  • Figure 4.8.1 Jubilant Financial Highlights 2011-2015 ($/m)
  • Figure 4.8.2 Jubilant Revenue, by Geography, FY2015 (%)
  • Figure 4.9.1 Torrent Financial Highlights 2011-2015 ($/m)
  • Figure 4.9.2 Torrent Revenue, by Geography, FY2015 (%)
  • Figure 4.10.1 Wockhardt Financial Highlights 2011-2015 ($/m)

Companies Mentioned

  • Abbott
  • AbbVie
  • Actelion
  • Agila Specialities
  • Amgen
  • Amgen
  • ANVISA Brazil
  • Apotex Inc
  • Aptil Pharma Limited
  • Arab Company for Drug Industries and Medical Appliances
  • AstraZeneca
  • AstraZeneca Pharma India Limited (AZPIL)
  • BASF
  • Bayer Healthcare
  • Bayer Zydus Pharma
  • Betapharm
  • Biocon
  • Biopharm SPA
  • Bristol- Myers Squibb (BMS)
  • Cadila Healthcare
  • Capital Advisory Group
  • Caraco
  • Celeris
  • Celon Laboratories
  • Center of Excellence for Inhalation Research
  • Chattem
  • Cipla Ltd
  • Cipla Medpro
  • Claris Lifesciences
  • CP Pharmaceuticals
  • Curatio Healthcare
  • Daiichi Sankyo
  • Dishman Pharmaceuticals & Chemicals
  • Dr Reddy's Laboratories Ltd.
  • Dumex
  • Duomed Produtos Farmaceuticos
  • DUSA
  • Elder Pharmaceuticals Ltd
  • Endo Pharmaceuticals
  • Espharma GmbH
  • Farma World Importacao e Exportacao de Medicamentos LTDA
  • Fleming Labs
  • Fujifilm Diosynth Bio technologies
  • GAVIS Pharmaceuticals LLC
  • Generica KG Germany
  • Gilead Sciences Inc.
  • GlaxoSmithKline (GSK)
  • Glenmark Generics Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Health Canada
  • Heumann Pharma GmbH & Co.
  • Heunet Pharma GmbH Germany
  • Hospira
  • India Department of Industrial Policy and Promotion (DIPP)
  • India Planning Commission
  • Indian Ministry of Chemicals and Fertilizers
  • Insurance Regulatory and Development Authority of India
  • International Diabetes Federation (IDF)
  • IPCA Laboratories
  • IsoRay
  • Janssen Pharmaceutica N.V.
  • Japan PMDA
  • Jubilant Biosys Pte. Ltd.
  • Jubilant Cadista Pharmaceuticals Inc.
  • Jubilant Discovery Services Inc.
  • Jubilant HollisterStier General Partnership
  • Jubilant Life Sciences
  • Jubilant Life Sciences (Shanghai) Limited
  • Jubilant Life Sciences (USA) Inc.
  • Laboratories Grin S.A. de C.V.
  • Laboratorios Combix S.L
  • Laboratorios Torrent (Malaysia) SDN.BHD. Malaysia
  • Laboratorios Torrent, S.A. de C.V. Mexico
  • Litha
  • Lupin Ltd
  • MCC South Africa
  • Medicamenta a.s
  • Medicine San Frontier
  • Medpro Pharmaceutica (Pty) Ltd
  • Medquímica Indústria Farmacêutica S.A.,
  • Merck Serono
  • Merind
  • Mnemosyne Pharma. Inc.
  • Multicare Pharmaceuticals
  • Mylan
  • Nanomi BV
  • Natco Pharma
  • National Pharmaceutical Pricing Authority (NPPA)
  • Natrol
  • Negma,
  • Nesher Pharmaceuticals
  • Norispharm GmbH Germany
  • Novartis
  • Novel Laboratories Inc.
  • OctoPlus
  • Orchid Chemicals
  • Organisation for Economic Co-operation and Development (OECD)
  • Organisation of the Pharmaceutical Producers of India (OPPI)
  • Orion Corp.
  • Oscient Pharmaceuticals
  • Otsuka Pharmaceutical Co., Ltd
  • Panacea Biotec Ltd
  • Pfizer
  • Pharma Dynamics
  • Pinewood Laboratory
  • Piramal
  • PromiusPharma
  • Ranbaxy
  • Roche
  • S&D Pharma
  • Salix Pharmaceuticals
  • Sanofi
  • Societe Marocaine De Cooperation Pharmaceutique
  • Spimaco
  • Strides Arcolab Ltd
  • Sun Pharmaceutical Industries Ltd
  • Taro
  • Temmler Pharma GMBH & Co
  • The Pharmaceutical Institute (PHI).
  • Torrent Australasia Pty Ltd. Australia
  • Torrent Do Brasil Ltda Brazil
  • Torrent Pharma (Thailand) Co., Limited. Thailand
  • Torrent Pharma (UK) Ltd (TPUK) United Kingdom
  • Torrent Pharma Canada Inc. Canada
  • Torrent Pharma France S.A.S. France
  • Torrent Pharma GmbH (TPG) Germany
  • Torrent Pharma Inc. USA
  • Torrent Pharma Philippines Inc. Philippines
  • Torrent Pharma S.R.L. Romania
  • Torrent Pharmaceuticals Limited
  • UK Medicines & Healthcare products Regulatory Agency (UK MHRA / MHRA)
  • URL Pharma
  • US Federal Trade Commission
  • US Food & Drug Administration (USFDA / FDA)
  • Wallis Laboratory
  • Wockhardt Limited
  • World Bank
  • World Health Organisation (WHO)
  • World Trade Organization
  • Yoshindo Inc.
  • Zao Torrent Pharma Russia
  • Zydus BSV Pharma Pvt. Ltd.
  • Zydus Cadila
  • Zydus Cadila Healthcare Ltd
  • Zydus Discovery DMCC
  • Zydus Hospira Oncology Pvt. Ltd.
  • Zydus Takeda Healthcare Pvt. Ltd.
  • Zydus Worldwide DMCC
  • Zyg Pharma Private Limited
Back to Top